WO2009023164A3 - Induction of mucosal immunity - Google Patents

Induction of mucosal immunity Download PDF

Info

Publication number
WO2009023164A3
WO2009023164A3 PCT/US2008/009584 US2008009584W WO2009023164A3 WO 2009023164 A3 WO2009023164 A3 WO 2009023164A3 US 2008009584 W US2008009584 W US 2008009584W WO 2009023164 A3 WO2009023164 A3 WO 2009023164A3
Authority
WO
WIPO (PCT)
Prior art keywords
mucosal immunity
induction
inducing
cell
methods
Prior art date
Application number
PCT/US2008/009584
Other languages
French (fr)
Other versions
WO2009023164A2 (en
Inventor
Marc Lipsitch
Richard Malley
Krzysztof Trzcinski
Original Assignee
Harvard College
Childrens Hospital Boston
Marc Lipsitch
Richard Malley
Krzysztof Trzcinski
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harvard College, Childrens Hospital Boston, Marc Lipsitch, Richard Malley, Krzysztof Trzcinski filed Critical Harvard College
Publication of WO2009023164A2 publication Critical patent/WO2009023164A2/en
Publication of WO2009023164A3 publication Critical patent/WO2009023164A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/544—Mucosal route to the airways
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The invention provides compositions and methods of inducing CD4+ T cell-mediated mucosal immunity against select antigens to which an antibody response does not confer clinical benefit.
PCT/US2008/009584 2007-08-10 2008-08-11 Induction of mucosal immunity WO2009023164A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US96437707P 2007-08-10 2007-08-10
US60/964,377 2007-08-10

Publications (2)

Publication Number Publication Date
WO2009023164A2 WO2009023164A2 (en) 2009-02-19
WO2009023164A3 true WO2009023164A3 (en) 2009-04-09

Family

ID=40202884

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/009584 WO2009023164A2 (en) 2007-08-10 2008-08-11 Induction of mucosal immunity

Country Status (1)

Country Link
WO (1) WO2009023164A2 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006032472A2 (en) * 2004-09-22 2006-03-30 Glaxosmithkline Biologicals S.A. Immunogenic composition for use in vaccination against staphylococcei
WO2006122986A2 (en) * 2005-05-20 2006-11-23 Institut Pasteur Use of penicillin-binding proteins or polynucleotides or antibodies thereof for preventing or treating bacterial infections

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006032472A2 (en) * 2004-09-22 2006-03-30 Glaxosmithkline Biologicals S.A. Immunogenic composition for use in vaccination against staphylococcei
WO2006122986A2 (en) * 2005-05-20 2006-11-23 Institut Pasteur Use of penicillin-binding proteins or polynucleotides or antibodies thereof for preventing or treating bacterial infections

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BASSET ALAN ET AL: "Antibody-independent, CD4(+) T-Cell-Dependent protection against pneumococcal colonization elicited by intranasal immunization with purified pneumococcal proteins", INFECTION AND IMMUNITY, vol. 75, no. 11, November 2007 (2007-11-01), pages 5460 - 5464, XP002510337, ISSN: 0019-9567 *
BINA XIAOWEN R ET AL: "The Bla2 beta-lactamase from the live-vaccine strain of Francisella tularensis encodes a functional protein that is only active against penicillin-class beta-lactam antibiotics", ARCHIVES OF MICROBIOLOGY, vol. 186, no. 3, September 2006 (2006-09-01), pages 219 - 228, XP019419711, ISSN: 0302-8933 *
GREEN M ET AL: "Efficacy of the live attenuated Francisella tularensis vaccine (LVS) in a murine model of disease", VACCINE, BUTTERWORTH SCIENTIFIC. GUILDFORD, GB, vol. 23, no. 20, 8 April 2005 (2005-04-08), pages 2680 - 2686, XP004789525, ISSN: 0264-410X *
OHWADA AKIHIKO ET AL: "DNA vaccination by mecA sequence evokes an antibacterial immune response against methicillin-resistant Staphylococcus aureus", JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, vol. 44, no. 6, December 1999 (1999-12-01), pages 767 - 774, XP002510336, ISSN: 0305-7453 *
SENNA J P M ET AL: "Protective immune response against methicillin resistant Staphylococcus aureus in a murine model using a DNA vaccine approach", VACCINE, BUTTERWORTH SCIENTIFIC. GUILDFORD, GB, vol. 21, no. 19-20, 2 June 2003 (2003-06-02), pages 2661 - 2666, XP004424180, ISSN: 0264-410X *
TRZCINSKI KRZYSZTOF ET AL: "Protection against nasopharyngeal colonization by Streptococcus pneumoniae antigen-specific CD4(+) T cells", INFECTION AND IMMUNITY, vol. 76, no. 6, June 2008 (2008-06-01), pages 2678 - 2684, XP002510338, ISSN: 0019-9567 *

Also Published As

Publication number Publication date
WO2009023164A2 (en) 2009-02-19

Similar Documents

Publication Publication Date Title
WO2007100908A3 (en) Chimeric adenoviral vectors
WO2013054199A3 (en) Cmv antigens and uses thereof
WO2009025888A3 (en) Regulated synthesis of antigen and/or regulated attentuation to enhance vaccine immunogenics and/or safety
WO2008116078A3 (en) Stimulation of an immune response by cationic lipids
WO2015117008A3 (en) Broadly neutralizing anti-hiv antibodies and epitope therefor
WO2007120673A3 (en) Immunogenic wt-1 peptides and methods of use thereof
WO2008097866A3 (en) Vaccines based on targeting antigen to dcir expressed an antigen-presenting cells
IL232518A0 (en) Yeast-based vaccine for inducing an immune response
WO2011109833A3 (en) Induced dendritic cell compositions and uses thereof
WO2012027365A3 (en) Targeted multi-epitope dosage forms for induction of an immune response to antigens
WO2009126688A3 (en) Novel compositions and methods for the treatment of immune related diseases
EA201300585A1 (en) Immunomodulatory Oligonucleotides
WO2012064836A9 (en) Methods and compositions for neural disease immunotherapy
MX2013001473A (en) Antibodies against il-18r1 and uses thereof.
WO2014078268A3 (en) Anti-hemagglutinin antibodies and methods of use
WO2006107924A3 (en) Ehrlichia canis diva (differentiate infected from vaccinated animals)
JO3437B1 (en) Improved anti human Fraktalkine antibodies and uses thereof
ZA201003964B (en) Compositions for and methods of enhancing the immune response to antigens
IN2014CN03454A (en)
WO2008043000A3 (en) Ehrlicia canis diva (differentiate infected from vaccinated animals)
WO2014151834A3 (en) Methods and compositions relating to anti-ccr7 antigen binding proteins
MX2009005381A (en) Canine leishmania vaccine.
PT2231196T (en) Increase of immune response by peptide antigen linkage
WO2013082500A3 (en) Vaccine for falciparum malaria
WO2007120603A3 (en) Immunogenic bcr-abl peptides and methods of use thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08795193

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08795193

Country of ref document: EP

Kind code of ref document: A2